BFM
IMUX icon

Boothbay Fund Management’s Immunic IMUX Stock Holding History

Boothbay Fund Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,430
Closed -$201K – 1607
2025
Q1 		$201K Hold
18,430
– – 0.01% 1165
2024
Q4 		$184K Buy
+18,430
New +$232K ﹤0.01% 1215

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's IMUX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Immunic (IMUX) in Q1 2026, closing a stake of 13,059 shares — an estimated $69.7K sold.

Boothbay Fund Management first reported a position in IMUX in Q3 2018 and held it in 17 quarters. The position peaked at $699K in Q3 2024. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Boothbay Fund Management reported no remaining Immunic position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 13,059 Immunic shares in Q1 2026, an estimated $69.7K.
  • Boothbay Fund Management first reported a position in Immunic in Q3 2018 and held it in 17 quarters.
  • Boothbay Fund Management's Immunic position peaked at $699K in Q3 2024.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.